Precipio (NASDAQ:PRPO) Raised to “Buy” at Wall Street Zen

Precipio (NASDAQ:PRPO) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Precipio in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Precipio Stock Performance

Shares of NASDAQ:PRPO opened at $25.40 on Friday. The firm has a fifty day moving average of $24.93 and a two-hundred day moving average of $22.95. The firm has a market capitalization of $45.21 million, a P/E ratio of -101.60 and a beta of 1.19. Precipio has a 12-month low of $3.90 and a 12-month high of $29.53. The company has a quick ratio of 1.10, a current ratio of 1.27 and a debt-to-equity ratio of 0.06.

Precipio (NASDAQ:PRPO) last posted its quarterly earnings results on Monday, March 30th. The biotechnology company reported $0.34 earnings per share for the quarter. Precipio had a negative net margin of 1.51% and a negative return on equity of 2.89%. The business had revenue of $6.70 million for the quarter.

Institutional Trading of Precipio

Large investors have recently added to or reduced their stakes in the business. AMH Equity Ltd increased its stake in shares of Precipio by 370.1% during the 3rd quarter. AMH Equity Ltd now owns 131,100 shares of the biotechnology company’s stock worth $2,332,000 after purchasing an additional 103,210 shares during the last quarter. Evernest Financial Advisors LLC acquired a new stake in shares of Precipio in the 3rd quarter valued at $374,000. Topline Capital Management LLC acquired a new stake in shares of Precipio in the 3rd quarter valued at $1,158,000. Susquehanna International Group LLP bought a new stake in Precipio in the third quarter worth $194,000. Finally, Geode Capital Management LLC boosted its holdings in Precipio by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 789 shares in the last quarter. 10.45% of the stock is owned by institutional investors.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.